CN1424104A - Medicines for treating chronic prostatitis and preparation thereof - Google Patents
Medicines for treating chronic prostatitis and preparation thereof Download PDFInfo
- Publication number
- CN1424104A CN1424104A CN 02159231 CN02159231A CN1424104A CN 1424104 A CN1424104 A CN 1424104A CN 02159231 CN02159231 CN 02159231 CN 02159231 A CN02159231 A CN 02159231A CN 1424104 A CN1424104 A CN 1424104A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- weight
- salviae miltiorrhizae
- linderae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine in the form of capsule for treating chronic prostatitis is prepared from 10 Chinese-medicinal diseases including red sage root, cat-tail pollen, notoginseng, rhubarb, etc. Its advantages are high curative effect and no toxic by-effect.
Description
Technical field
The present invention relates to treat the medicine of chronic prostatitis, specifically, be a kind of be the Chinese patent medicine and preparation method thereof of feedstock production with the Chinese herbal medicine.
Background technology
Prostate is an attached gonad maximum in the male genital organ, is positioned at pelvic cavity, is cone shape, the likeness in form Semen Castaneae.Prostatic major function is the secretion prostatic fluid, and some composition (accounting for the 15%-30% of seminal fluid) in the supply seminal fluid is subjected to androgenic control, and is extremely important to giving birth to.Prostatic fluid is generally taked with per rectum massage prostate, and the analysis of prostatic fluid is to understanding prostatic physiology and diagnosing significant.About 4 * 3 * 2cm of normal prostatic size (wide * long * thick), heavily about 20 grams.Prostatic structure and age are closely related, and its prostate of young boy is less, and to pubarche growth, 20-50 year, prostate volume is relatively stable, and body of gland begins hypertrophy again after 50 years old, and may send out benign prostatic hyperplasia this moment.
Chronic prostatitis is a kind of sickness rate height (accounting for the adult male more than 25%), treats thorny disease, clinical symptoms complexity, recurrence easily.Common symptom is a dysuria, pain, and sexual dysfunction such as libido attenuating, premature ejaculation, sexual impotence etc., neurasthenia symptom is as dizziness, headache, insomnia, spirit depressing etc.
Patients with chronic prostatitis generally adopts the antibiotic therapy unsatisfactory curative effect, and this is because have major part to belong to agnogenic non-bacteria inflammation in the chronic prostatitis, and is irrelevant with bacterial infection.Also have fraction to belong to the unclear prostatodynia of the cause of disease, its main pathology is the myalgia that pelvic diaphragm muscle contracture and spasm etc. cause.In addition, because the barrier permeability that capsula prostatica forms is poor, antibacterials are difficult for infiltrating this one and reach valid density, also are one of reasons of antibiotic therapy poor effect.
In recent years, also disclosing some successively relevant is the medicine of the treatment chronic prostatitis produced of raw material with the Chinese herbal medicine, as the CN1219421A patent application, with 13 flavor prepared from traditional Chinese medicines " medicine of treatment chronic bacterial prostatitis " such as Flos Lonicerae, Herba Violae, living Radix Glycyrrhizae, the Rhizoma Anemarrhenaes; Then be to be the capsule that raw material makes also with 10 Chinese medicine medicines such as Flos Chrysanthemi Indici, Typhonium flagelliforme (Lodd.) Blume, Semen Coicis, Semen Plantaginis, Pollen Tyjphae as the CN1220145A patent application.The effect of drugs of the treatment chronic prostatitis that different Chinese herbal medicine formulas makes is different.
Summary of the invention
The purpose of this invention is to provide a kind of medicine that effects such as antiinflammatory, antibiotic, spasmolytic, diuresis, pain relieving are the treatment chronic prostatitis produced of raw material obviously and with the Chinese herbal medicine that has.
Medicine of the present invention is the medicament that makes with following materials based on weight:
Radix Salviae Miltiorrhizae 700-1100 part, Pollen Typhae 300-800 part, Radix Notoginseng 70-110 part, Radix Et Rhizoma Rhei 150-650 part, Radix Linderae 150-650 part, Fructus Evodiae 150-650 part, Cortex Phellodendri 400-800 part, Radix Sophorae Flavescentis 300-700 part, Herba Taraxaci 400-800 part, Radix Trichosanthis 700-1100 part.
Medicine of the present invention fill a prescription preferably (in parts by weight) be:
Radix Salviae Miltiorrhizae 800-1000 part, Pollen Typhae 400-680 part, Radix Notoginseng 80-100 part, Radix Et Rhizoma Rhei 250-450 part, Radix Linderae 250-450 part, Fructus Evodiae 250-450 part, Cortex Phellodendri 500-700 part, Radix Sophorae Flavescentis 400-600 part, Herba Taraxaci 500-700 part, Radix Trichosanthis 80-100 part.
Medicine optimum formula of the present invention (in parts by weight) is:
900 parts of Radix Salviae Miltiorrhizaes, 540 parts of Pollen Typhaes, 90 parts of Radix Notoginseng, 360 parts of Radix Et Rhizoma Rhei, 360 parts of the Radixs Linderae, 360 parts of Fructus Evodiaes, 600 parts of Cortex Phellodendris, 540 parts of Radix Sophorae Flavescentiss, 600 parts of Herba Taraxacis, 900 parts of Radix Trichosanthis.
Pharmaceutical preparation of the present invention is capsule, and its preparation method comprises following process:
(1) gets 700-1100 part Radix Salviae Miltiorrhizae, add the ethanol of 8 times of Radix Salviae Miltiorrhizae weight therein, refluxed 1.5 hours, filter, it is 1.26 extractum that filtrate is evaporated to relative density in 55-60 ℃, the Radix Notoginseng powder that adds 70-110 part in extractum, mixing, vacuum drying, Radix Salviae Miltiorrhizae decoction dregs is standby;
(2) get 150-650 part Radix Linderae and 150-650 part Fructus Evodiae, 6 times of water that add the Radix Linderae and Fructus Evodiae weight, soak steam distillation after 1 hour, extract volatile oil, extraction time is 8 hours, 6 times the beta-schardinger dextrin-that in volatile oil, adds volatile oil weight then, be dissolved in again in 100 times of water of volatile oil and β-Cyclodextrin weight, 50 ℃ of following enclose 1 hour, refrigerator and cooled was hidden 24 hours, filter, the clathrate that obtains was in 50 ℃ of bakings 3 hours, and it is standby after filtering to extract the Aromatic water and the medicinal residues that obtain behind the volatile oil;
(3) Radix Linderae, the Fructus Evodiae medicinal residues with 300-800 part Pollen Typhae, 150-650 part Radix Et Rhizoma Rhei, 400-800 part Cortex Phellodendri, 300-700 part Radix Sophorae Flavescentis, 400-800 part Herba Taraxaci, 700-1100 part Radix Trichosanthis and step (1) Radix Salviae Miltiorrhizae decoction dregs and step (2) mix, 12 times the water that adds its weight, reflux, extract, 2 times, each 2 hours, obtain extracting solution;
(4) Aromatic water of the extracting solution of step (3) and step (2) merges, and is concentrated into relative density 1.13, and adding ethanol, to transfer to determining alcohol be 75%, placed 30 minutes, centrifugal, get supernatant, reclaim ethanol, vacuum drying, dry product that the dry product of gained and step (1) and step (2) obtain merges weighs, and adds starch to 1000 part, pulverizes, mix homogeneously, the encapsulated required product that promptly obtains.
Medicine of the present invention cure mainly difficulty and pain in micturition that acute and chronic prostatitis causes, the heeltap not to the utmost, perineum, lower abdomen and testicular pain, hyposexuality, pain in the lumbar region, prostatic fluid is conventional unusual etc.; Usage and consumption: oral, one time 4, three times on the one, 1 month course of treatment; Store method: airtight, shady and cool dry place preserves 2 years shelf-lifves.
Advantage of the present invention and effect:
Medicine of the present invention is based on blood circulation promoting and blood stasis dispelling, and assistant at the main pathology link of chronic prostatitis, promotes local blood circulation and drug absorption with the clearing away heat-damp and promoting diuresis antiinflammatory, can alleviate spasmic pain, inducing diuresis for treating stranguria syndrome; Also by integrally-regulated, improve General Symptoms simultaneously as the insomnia anxiety, sexual dysfunction etc., human body immunity improving power, prevention reduces recurrence; Drug efficacy study confirms: medicine of the present invention has good antiinflammation, the effect that having regulates the flow of vital energy relieves the pain, and mice normally reaches water load diuretic test result and shows tangible inducing diuresis for treating stranguria syndrome effect.Clinical observation shows that medicine of the present invention has ideal curative effect to chronic prostatitis, and the acute and chronic toxicological experiment shows, has no side effect.
In order to confirm the effect of medicine of the present invention, through hospital's 120 routine clinical observations, report content is as follows:
Object of study and method
One, object of study
Allly meet CP Western medicine diagnose standard and get rid of case standard person, all can include the object of study scope in.120 routine patients are nineteen ninety-five JIUYUE to the 1996 air force general hospital department of Chinese medicine in year April and the outpatient of andrology.Western medicine diagnose standard reference " diagnostics " (Qi Renduo chief editor, Beijing: People's Health Publisher, 1993:501), " clinical disease diagnosis standard and national health check-up standard " (chief editor such as Yu Dechun, front page, Liaoning: Liaoning science tech publishing house, 1991:61) and according to this paper EPS experimental check index formulate; (first volume, Beijing: Ministry of Health of the People's Republic of China makes and issue, 1993:192-206) to get rid of case standard reference " new Chinese medicine clinical research guideline "
Two, observation item
The patient carries out the subjective symptom inquiring before and after treatment, comprise pain or malaise symptoms, urinary tract symptom, property and four groups of symptoms such as reproduction symptom and General Symptoms; Whether the prostate touch unusual, comprise unusually large and small, hard, bitterly, six aspects such as heat, knot; The relative analysis of EPS objective determination comprises EPS-PH pH-value determination pH, EPS routine and differs the microimaging inspection.
Three, Therapeutic Method
Before the treatment, have a blood test, urine, stool routine examination regulating liver-QI, renal function, normal person's administration.After one month, check blood, urine, stool routine examination regulating liver-QI, renal function.
Shu An capsule (product of the present invention, as follows) is 4/time before the treatment, and every day three times, continuous use 1 month does not add during the treatment and uses other medicines, carries out observation of curative effect research.
Four, clinical efficacy
1. doing well,improving situation
To CP doing well,improving situation, we observe from pain or malaise symptoms, urinary tract symptom, property and reproduction symptom and four aspects of General Symptoms, the results are shown in Table 1 for the ease of Shu An before inquiring into.
| Symptom | n | Recovery from illness | Produce effects | Take a turn for the better | Invalid | Effectively (%) |
| Pain or uncomfortable urinary tract symptom and reproduction symptom | 102 118 96 | ?34 ?55 ?33 | ?27 ?24 ?18 | ?30 ?39 ?21 | ?11 ?0 ?24 | ?89.22 ?100.00 ?75.00 |
| General Symptoms | 104 | ?45 | ?12 | ?37 | ?10 | ?90.39 |
Table 1 shows, preceding Shu An all has a better role to the pain of CP or malaise symptoms, urinary tract symptom, property and reproduction symptom and General Symptoms, and is good especially to the urinary tract symptom curative effect.
2. prostate touch situation
Prostate touch situation analysis relatively can reflect the improvement effect of medicine to the local sign of prostate, the results are shown in Table 2.
The prostate touch changes (n=120) before and after table 2 treatment
| Recovery from illness | Produce effects | Take a turn for the better | Invalid | Effectively (%) |
| 56 | ?27 | ?15 | ?22 | ?81.67％ |
Table 2 shows that preceding Shu An has better action to the local sign of prostate, the recovery from illness example, and produce effects 27 examples, the recovery from illness obvious effective rate is 69.17%, total effective rate 81.67%.
3.EPS-pH change
The EPS-pH value compares (X ± SD) (n=120) before and after table 3 treatment
| Before the treatment | After the treatment | P |
| 6.81±0.27 | 6.34±0.24 | ＜0.01 |
Table 3 shows, descends before treatment back EPS-pH value is treated very obviously (P＜0.01).Shu Anneng descends the EPS-pH value of CP before illustrating, and effect is obvious.
4.EPS routine examination situation
(1) EPS lecithin
Can occur normally before the EPS lecithin treatment of CP, treatment back change can reduce because of the disease end of loveization.Therefore in order to add up convenient, we adopt ranked data, and lecithin is covered with the visual field (+++), a large amount of (++), (+) in a small amount, and regulation +++be 3 minutes, ++ be 2 minutes ,+be 1 minute, the results are shown in Table 4.
EPS lecithin score value compares (X ± SD) (n+120) before and after table 4 treatment
| Before the treatment | After the treatment | ????P |
| ????1.75±0.58 | ????1.73±0.71 | ????＞0.05 |
Table 4 shows, difference (P＞0.05) that there are no significant before treatment back lecithin was treated, and its reason may not have specificity with this index of lecithin, and changes more relevant during the treatment.
2.EPS leukocyte the results are shown in Table 5.
The leukocytic variation of EPS (n=120) before and after table 5 treatment
| Normally | Reduce | Do not have and improve | Effectively (%) |
| 32 | ????62 | ????26 | ??78.33 |
Table 5 shows, treatment back EPS leukopenia, and effective percentage 78.33%, Shu An is inhibited to the inflammatory reaction of CP before showing.
5. side effect is observed
120 routine CP patients do not have significant discomfort behind the Shu An capsule before taking, and blood, urine, stool routine examination regulating liver-QI, kidney function test are all normal.
6. comprehensive therapeutic effect evaluation
With reference to the therapeutic evaluation standard, 120 routine CP patients cure 54 examples (45.00%), produce effects 27 examples (8.33%), and 22 examples that take a turn for the better (18.33%), invalid 17 examples (14.1%) the results are shown in Table 6.
Table 6 comprehensive therapeutic effect evaluation (n=120)
| Recovery from illness | Produce effects | Take a turn for the better | Invalid | Effectively (%) |
| ??54 | ??27 | ??22 | ??17 | ??85.83％ |
Table 6 shows that preceding Shu An has the good curing effect to CP, recovery from illness+produce effects 81 examples (67.50%), total effective rate 85.83%.
Five. the mechanism of action
1. reduce the EPS-pH value
About the EPS-pH value rising reason of CP, we think that this may have ureaplasma urealyticum infection relevant by CP.Because urine easily blows back into prostate, provide required carbamide for separating the former bulk-growth of rami glandulares, and Ureaplasma urealyticum itself has urease, and the energy decomposing urea produces NH3, and (Cao Yupu etc. write, and go into the laboratory diagnosis technology of mycoplasma infection, Beijing: Chinese Medical Association's microorganism and immunology meeting mycoplasma group, 1992:28-29), the EPS-pH value of slant acidity is raise, very person's meta-alkalescence, destroy the acid-base balance of EPS, caused the prostate dysfunction.Preceding Shu An treatment back EPS-pH value descends, and illustrates that this medicine has the effect of killing Ureaplasma urealyticum, thereby the EPS-pH value is descended.
2. promote that the drainage of prostate conduit is unobstructed
The alluvial of EPS leukocyte is in heaps, is the microcosmic sign of prostate conduit drainage difficulty.Can not illustrate with the disappearance that urethra drips white phenomenon clinically the prostate conduit drain unobstructed because this might be the result of PD.Generally think, EPS leukocyte rickle, in heaps, a large amount of inflammation scope that reflects the prostate conduit respectively in heaps, rickle is that 1-2 root conduit inflammation is blocked, and in heaps is that 3-5 root conduit inflammation is blocked, and in heaps in a large number is that many conduit inflammation are blocked.Preceding Shu An makes the EPS leukopenia, illustrates that this medicine has promotion prostate conduit to drain unobstructed effect, from the inflammatory reaction with inhibition CP.
The specific embodiment
Further specify the characteristics of medicine of the present invention below by instantiation.
Example 1-3
Example 1-3 is pharmaceutical compositions of the present invention and preparation process thereof, and the medicine material prescription sees Table 7.
Table 7 pharmaceutical formulation (unit: g)
| Project | Example 1 | Example 2 | Example 3 |
| Radix Salviae Miltiorrhizae | ????900 | ????750 | ????1000 |
| Pollen Typhae | ????540 | ????700 | ????350 |
| Radix Notoginseng | ????90 | ????80 | ????100 |
| Radix Et Rhizoma Rhei | ????360 | ????550 | ????160 |
| The Radix Linderae | ????360 | ????200 | ????600 |
| Fructus Evodiae | ????360 | ????600 | ????300 |
| Cortex Phellodendri | ????600 | ????500 | ????700 |
| Radix Sophorae Flavescentis | ????540 | ????700 | ????350 |
| Herba Taraxaci | ????600 | ????450 | ????750 |
| Radix Trichosanthis | ????900 | ????850 | ????1000 |
Concrete preparation method:
8 times the ethanol that adds Radix Salviae Miltiorrhizae weight in Radix Salviae Miltiorrhizae refluxed 1.5 hours, filtered, and it is 1.26 that filtrate is evaporated to relative density in 55-60 ℃, adds Radix Notoginseng powder in the extractum that obtains, mixing, and vacuum drying, Radix Salviae Miltiorrhizae decoction dregs is standby; The water logging that adds 6 times of its weight in the Radix Linderae and the Fructus Evodiae was steeped 1 hour, water vapour distillation volatile oil, 8 hours extraction times, add 6 times of beta-schardinger dextrin-s in the volatile oil, be dissolved in 100 times of water, 50 ℃ of following enclose 1 hour, refrigerator and cooled is hidden and is spent the night, filter, clathrate was in 50 ℃ of oven dry 3 hours, and Aromatic water and medicinal residues are standby; Get other 6 flavor medicine and mix, add 12 times of water of its weight, reflux and carry 2 times with Radix Salviae Miltiorrhizae decoction dregs and the Radix Linderae, Fructus Evodiae medicinal residues, each 2 hours, extracting solution and Aromatic water merged, and being concentrated into relative density is 1.13, adding ethanol, to transfer to determining alcohol be 75%, leaves standstill 30 minutes, centrifugal, get supernatant, reclaim ethanol, vacuum drying, get above-mentioned three kinds of dry products and weigh, add starch to 1000 gram, pulverize, mix homogeneously, encapsulated.
Claims (5)
1. a treatment chronic prostatitis medicine is characterized in that it is the medicament that is made by following materials based on weight: Radix Salviae Miltiorrhizae 700-1100 part, Pollen Typhae 300-800 part, Radix Notoginseng 70-110 part, Radix Et Rhizoma Rhei 150-650 part, Radix Linderae 150-650 part, Fructus Evodiae 150-650 part, Cortex Phellodendri 400-800 part, Radix Sophorae Flavescentis 300-700 part, Herba Taraxaci 400-800 part, Radix Trichosanthis 700-1100 part.
2. medicine according to claim 1 is characterized in that it is the medicament that is made by following materials based on weight: Radix Salviae Miltiorrhizae 800-1000 part, Pollen Typhae 400-680 part, Radix Notoginseng 80-100 part, Radix Et Rhizoma Rhei 250-450 part, Radix Linderae 250-450 part, Fructus Evodiae 250-450 part, Cortex Phellodendri 500-700 part, Radix Sophorae Flavescentis 400-600 part, Herba Taraxaci 500-700 part, Radix Trichosanthis 80-100 part.
3. medicine according to claim 1 is characterized in that it is the medicament that is made by following materials based on weight: 900 parts of Radix Salviae Miltiorrhizaes, 540 parts of Pollen Typhaes, 90 parts of Radix Notoginseng, 360 parts of Radix Et Rhizoma Rhei, 360 parts of the Radixs Linderae, 360 parts of Fructus Evodiaes, 600 parts of Cortex Phellodendris, 540 parts of Radix Sophorae Flavescentiss, 600 parts of Herba Taraxacis, 900 parts of Radix Trichosanthis.
4. according to claim 1,2 or 3 described medicines, it is characterized in that described medicament is a capsule.
5. process for preparing medicine according to claim 4 is characterized in that described capsular preparation process may further comprise the steps:
(1) gets 700-1100 part Radix Salviae Miltiorrhizae, add the ethanol of 8 times of Radix Salviae Miltiorrhizae weight therein, refluxed 1.5 hours, filter, it is 1.26 extractum that filtrate is evaporated to relative density in 55-60 ℃, the Radix Notoginseng powder that adds 70-110 part in extractum, mixing, vacuum drying, Radix Salviae Miltiorrhizae decoction dregs is standby;
(2) get 150-650 part Radix Linderae and 150-650 part Fructus Evodiae, 6 times of water that add the Radix Linderae and Fructus Evodiae weight, soak steam distillation after 1 hour, extract volatile oil, extraction time is 8 hours, 6 times the beta-schardinger dextrin-that in volatile oil, adds volatile oil weight then, be dissolved in again in 100 times of water of volatile oil and β-Cyclodextrin weight, 50 ℃ of following enclose 1 hour, refrigerator and cooled was hidden 24 hours, filter, the clathrate that obtains was in 50 ℃ of bakings 3 hours, and it is standby after filtering to extract the Aromatic water and the medicinal residues that obtain behind the volatile oil;
(3) Radix Linderae, the Fructus Evodiae medicinal residues with 300-800 part Pollen Typhae, 150-650 part Radix Et Rhizoma Rhei, 400-800 part Cortex Phellodendri, 300-700 part Radix Sophorae Flavescentis, 400-800 part Herba Taraxaci, 700-1100 part Radix Trichosanthis and step (1) Radix Salviae Miltiorrhizae decoction dregs and step (2) mix, 12 times the water that adds its weight, reflux, extract, 2 times, each 2 hours, obtain extracting solution;
(4) Aromatic water of the extracting solution of step (3) and step (2) merges, and is concentrated into relative density 1.13, and adding ethanol, to transfer to determining alcohol be 75%, placed 30 minutes, centrifugal, get supernatant, reclaim ethanol, vacuum drying, dry product that the dry product of gained and step (1) and step (2) obtain merges weighs, and adds starch to 1000 part, pulverizes, mix homogeneously, the encapsulated required product that promptly obtains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021592314A CN1195540C (en) | 2002-12-27 | 2002-12-27 | Medicines for treating chronic prostatitis and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021592314A CN1195540C (en) | 2002-12-27 | 2002-12-27 | Medicines for treating chronic prostatitis and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1424104A true CN1424104A (en) | 2003-06-18 |
| CN1195540C CN1195540C (en) | 2005-04-06 |
Family
ID=4753270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021592314A Expired - Fee Related CN1195540C (en) | 2002-12-27 | 2002-12-27 | Medicines for treating chronic prostatitis and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1195540C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757310A (en) * | 2009-08-10 | 2010-06-30 | 黄山 | Pill for treating prostatitis |
| CN101954037A (en) * | 2010-10-18 | 2011-01-26 | 吴伶 | Chinese medicinal preparation for treating prostatitis |
| CN101721528B (en) * | 2009-12-30 | 2011-09-07 | 长春中医药大学 | Medicine composition for treating chronic prostatitis |
| CN102743567A (en) * | 2012-06-30 | 2012-10-24 | 张晨 | Traditional Chinese medicine for treating chronic prostatitis |
-
2002
- 2002-12-27 CN CNB021592314A patent/CN1195540C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757310A (en) * | 2009-08-10 | 2010-06-30 | 黄山 | Pill for treating prostatitis |
| CN101721528B (en) * | 2009-12-30 | 2011-09-07 | 长春中医药大学 | Medicine composition for treating chronic prostatitis |
| CN101954037A (en) * | 2010-10-18 | 2011-01-26 | 吴伶 | Chinese medicinal preparation for treating prostatitis |
| CN101954037B (en) * | 2010-10-18 | 2011-10-19 | 吴伶 | Chinese medicinal preparation for treating prostatitis |
| CN102743567A (en) * | 2012-06-30 | 2012-10-24 | 张晨 | Traditional Chinese medicine for treating chronic prostatitis |
| CN102743567B (en) * | 2012-06-30 | 2013-08-21 | 艾芹 | Traditional Chinese medicine for treating chronic prostatitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1195540C (en) | 2005-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101195008B (en) | Cattail pollen skin cleaning agent for treating gynecology disease and technique of preparing the same thereof | |
| CN101049415A (en) | Preparation of Chinese traditional medicine for treating inflammation of department of gynecology | |
| CN1733138A (en) | Medicine for curing animal barrenness | |
| CN101214357A (en) | Pharmaceutical composition for treating chronic prostatitis | |
| CN101584758A (en) | A kind of pharmaceutical composition for the treatment of kidney deficiency | |
| CN101288754B (en) | Huyuebao preparation | |
| CN1927322A (en) | Liposoluble traditional medicine bougie for treating acute and chronic prostatitis, and manufacturing technique thereof | |
| CN100579562C (en) | Oral Chinese medicine composition for treating constipation | |
| CN103041262B (en) | Traditional Chinese medicine enema for curing chronic prostatitis and preparing method thereof | |
| CN101618129B (en) | Chinese medical preparation for treating rheumatoid osteopathia | |
| CN1195540C (en) | Medicines for treating chronic prostatitis and preparation thereof | |
| CN1251748C (en) | Lotion for treating gynecological disease and its preparation process | |
| CN1364628A (en) | Compound Chinese medicinal preparation for treating chronic diarrhea-chronic Xiehanning pill | |
| CN101249208B (en) | Proprietary Chinese medicine preparations for curing chronic emphraxis lung diseases | |
| CN101045152A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling | |
| CN1443545A (en) | Medicine for curing acne and its preparation method | |
| CN101623457B (en) | Traditional Chinese medicine for treating chronic prostatitis | |
| CN1686272A (en) | Medicine for treating chronic prostatitis and its preparation method | |
| CN1765381A (en) | Conditioning qi-invigorating weight-reducing extract | |
| CN1965945A (en) | Tincture having ageratum and mint for treating heat rash | |
| CN1772239A (en) | Chinese medicine prepn for treating vaginitis and cervicitis | |
| CN1269518C (en) | Compound medicine for treating tuberculosis and its preparing method | |
| CN102085267A (en) | Traditional Chinese medicinal washing liquid for treating female vulvitis | |
| KR102692595B1 (en) | Composition for treating and preventing constipation comprising Angelica gigas extract as an active ingredient | |
| CN1311851C (en) | Pill medicine for treating mastosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180228 Address after: 518000 Guangdong city of Shenzhen province Nanshan District Guangdong streets High-tech Zone technology community south twelve Road No. 012 Shuguang building 1205B Patentee after: Shenzhen Shuangbai Kang Pharmaceutical Technology Co.,Ltd. Address before: 100012 Beijing city Chaoyang District huizhongbeili No. 312 room 1705 Patentee before: Wang Qi |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050406 Termination date: 20211227 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |